Skip to main content

Table 1 The antibodies used in this study and their results

From: Salivary adenoid cystic carcinoma with an early phase of high-grade transformation: case report with an immunohistochemical analysis

  Antibody   ACC   HGT
Antigens Clone Source Cribriform Solid  
EMA E29 DakoCytomation (Carpinteria, CA, USA) + + ++
GCDFP-15 NCL-GCDFP15 Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
Her-2   DakoCytomation (Carpinteria CA) - 1+ 3+
EGFR NCL-L-EGFR Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
AR AR441 DakoCytomation (Carpinteria, CA, USA) - - -
CK5/6 D5/16 B4 DakoCytomation (Carpinteria, CA, USA) + + -(myo+)
S-100   DakoCytomation (Carpinteria, CA, USA) + + -
ASMA 1A4 DakoCytomation (Carpinteria, CA, USA) ++ + -
calponin CALP DakoCytomation (Carpinteria, CA, USA) + f+ -
CK14 LL002 Chemicon International (Temecula, CA, USA) + p+ -(myo+)
p63 4A4 Lab Vision (Fremont, CA, USA) ++ p+ -(myo+)
mammaglobin 304-1A5 DakoCytomation (Carpinteria, CA, USA) - f+  
p53 DO-7 DakoCytomation (Carpinteria, CA, USA) f+ p+ ++
cyclin A NCL-CYCLN A Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) 10.3% 17.3% 34.5%
cyclin B1 NCL-CYCLN B1 Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) 0.5% 12.2% 50.3%
cyclin D1 DSC-6 DakoCytomation (Carpinteria CA, USA) - 1.1% -
cylcin E NCL-CYCLN E Novocastra Laboratories Ltd. (New Castle Upon Tyne, UK) - - -
p16 G175-405 BD Biosciences (Franklin Lakes, NJ, USA) f+ p+ ++
MDM2 SMP14 Themo Fisher Scientific (Cheshire, UK) - - -
Ki-67L.I. MIB-1 DakoCytomation (Carpinteria, CA, USA) 34.5% 49.7% 73.2%
  1. ACC, adenoid cystic carcinoma area; HGT, high-grade transformation area.
  2. EMA, epithelial membrane antigen; GCDFP-15, gross cystic disease fluid protein-15; EGFR. Epidermal growth factor receptor; AR, androgen receptor; CK, cytokeratin; ASMA, alpha-smooth muscle actin.
  3. —, negative; f+, focally positive (1-9%); p+, partially positive (10-19%); +, positive (20-60%); ++, diffusely positive (>60%); myo, myoepithelial cells.